Quantcast
Last updated on April 18, 2014 at 17:08 EDT

Latest HBcAg Stories

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

2013-06-06 11:30:11

Researchers from Germany have found that low levels of vitamin D are associated with high levels of hepatitis B virus (HBV) replication. Findings published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggest seasonal fluctuations in vitamin D and HBV levels point to a link in these variables among patients with chronic HBV. While highly effective vaccines are available, HBV still remains one of the most significant infectious diseases...

2011-11-09 14:00:00

⢠96-week study in a population of nucleos(t)ide-naïve patients with chronic hepatitis B (CHB) infection ⢠Data presented at the American Association for the Study of Liver Diseases congress in San Francisco San Francisco, CA (PRWEB) November 09, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BEâLOWâ“ž¢ study, a Phase IIIb clinical trial comparing...

2010-11-01 08:35:00

BOSTON, Nov. 1, 2010 /PRNewswire/ -- Researchers studied the treatment of pregnant women with hepatitis B virus (HBV) with Telbivudine in their second to third trimesters. The study concluded that both the mothers benefited from treatment and no transmission of HBV to newborns was detected at 28 weeks postbirth. The study presenter and co-investigator Calvin Pan, MD, anticipates a "very powerful impact in the field, as hepatitis B is difficult to eradicate and currently there is no...

2010-02-10 09:10:21

Hepatitis B virus (HBV) genotypes have distinct geographical distributions, and have been shown to differ with regard to clinical outcome and prognosis. However, the relationship between HBV genotypes and liver cirrhosis remains controversial and no study on exploring the association between HBV genotypes and subclinical cirrhosis in community-based population has been reported. A research article to be published on January 21, 2010 in the World Journal of Gastroenterology addresses this...

2009-07-29 10:19:59

Hepatitis B virus (HBV) infection is a dynamic process with variable biochemical, virological and histological profiles at different stages of the infection, depending on host and viral factors. Furthermore, this profile may change at a variable pace over time. The correlation between detection of T-cell response and HBV load in chronic HBV infection remains unknown. In each of the clinical stages of chronic HBV infection, whether the composition of T-cell subpopulations is different and...

2008-11-03 09:00:40

Gilead Sciences, a biopharmaceutical company, has presented two-year data from two Phase III pivotal clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection. These new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of hepatitis B virus (HBV) levels in the blood (91% and 78% for Studies 102 and 103, respectively). The studies also show that all...